Xponance Inc. Buys 4,591 Shares of Gilead Sciences, Inc. $GILD

Xponance Inc. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 224,975 shares of the biopharmaceutical company’s stock after purchasing an additional 4,591 shares during the quarter. Xponance Inc.’s holdings in Gilead Sciences were worth $24,972,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of GILD. Vanguard Group Inc. lifted its stake in shares of Gilead Sciences by 1.6% in the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after buying an additional 1,893,401 shares during the period. Geode Capital Management LLC raised its holdings in Gilead Sciences by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after acquiring an additional 727,515 shares in the last quarter. Norges Bank bought a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $2,150,268,000. Invesco Ltd. increased its position in shares of Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after purchasing an additional 3,394,330 shares during the period. Finally, Amundi raised its stake in shares of Gilead Sciences by 18.2% in the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after purchasing an additional 1,614,355 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GILD has been the topic of several analyst reports. Cantor Fitzgerald boosted their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Royal Bank Of Canada raised their price target on shares of Gilead Sciences from $103.00 to $118.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 11th. Wells Fargo & Company lifted their price objective on Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Sanford C. Bernstein reissued an “outperform” rating and issued a $160.00 target price on shares of Gilead Sciences in a report on Wednesday, February 11th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Twenty-three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.72.

Gilead Sciences Trading Down 2.3%

GILD stock opened at $143.77 on Friday. The business has a fifty day moving average price of $135.61 and a 200 day moving average price of $124.58. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.31. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The stock has a market capitalization of $178.48 billion, a price-to-earnings ratio of 21.24, a P/E/G ratio of 1.93 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the previous year, the firm earned $1.90 earnings per share. The business’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s payout ratio is presently 48.45%.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the sale, the insider directly owned 120,288 shares of the company’s stock, valued at approximately $18,577,278.72. This trade represents a 18.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total value of $463,290.00. Following the sale, the chief financial officer owned 167,779 shares of the company’s stock, valued at approximately $25,910,110.97. The trade was a 1.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 299,280 shares of company stock valued at $42,487,570 over the last three months. 0.27% of the stock is owned by company insiders.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for $115 per share in cash, a $7.8 billion deal that boosts Gilead’s oncology/cell-therapy exposure and adds potential long‑term growth avenues. The transaction is material in size and supports the company’s pipeline diversification. Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy
• Positive Sentiment: New Phase 3 ARTISTRY data showed Gilead’s single‑tablet bictegravir/lenacapavir maintained virological suppression with low discontinuation rates — supportive for Gilead’s long‑acting HIV franchise and potential market share gains on switches. Gilead’s experimental HIV treatment shows low discontinuation rates in studies
• Positive Sentiment: Daiwa raised its price target to $161 and kept an “outperform” rating, implying notable upside versus current levels — a helpful analyst endorsement for sentiment. Daiwa Securities Adjusts Price Target on Gilead Sciences to $161
• Positive Sentiment: Zacks issued a series of upward EPS revisions across 2026–2028 (FY2026 to $8.54, FY2027 and FY2028 also raised) and lifted multiple quarterly estimates, which supports a stronger forward earnings outlook versus consensus. (Zacks research notes)
• Positive Sentiment: UBS reiterated a Buy and maintained a $175 price target, highlighting confidence in Gilead’s long‑acting HIV strategy. Gilead Sciences: Advancing Long-Acting HIV Franchise Underscores Competitive Edge and Supports Buy Rating
• Neutral Sentiment: Kymera Therapeutics reported strong results in its Q4 update — broadly positive for the biotech sector but not directly material to Gilead’s immediate fundamentals. Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights
• Negative Sentiment: Merck’s two‑drug HIV regimen matched Gilead’s Biktarvy in Phase 3 and is under FDA review — this increases competitive pressure in the core HIV market and could weigh on future market share/pricing. Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.
• Negative Sentiment: Zacks trimmed its Q3 2026 EPS estimate slightly (from $2.34 to $2.30), a modest near-term downtick in expectations that may contribute to selling pressure. (Zacks research note)

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.